指南与共识血栓与止血

ASCO癌症患者静脉血栓栓塞预防与治疗指南更新

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.
指南 / 共识 · J Clin Oncol · 2019-08-05

更新包括:高危门诊患者可选阿哌沙班、利伐沙班或低分子肝素(LMWH)预防;利伐沙班和艾多沙班新增为VTE治疗选项;脑转移患者纳入治疗章节;术后长期LMWH推荐扩展。重申多数住院癌症患者需全程预防,不常规推荐所有门诊患者预防,大手术后预防至少7-10天,应定期评估风险并教育患者。

要点

  • 高危门诊癌症患者可选阿哌沙班、利伐沙班或LMWH进行血栓预防。
  • 利伐沙班和艾多沙班新增为癌症相关VTE的治疗选项。
  • 大手术癌症患者预防应从术前开始并持续至少7-10天。

核心结论

  • 更新推荐:高危门诊癌症患者可选阿哌沙班、利伐沙班或LMWH预防;利伐沙班和艾多沙班新增为VTE治疗选项;脑转移患者纳入VTE治疗章节;术后长期LMWH推荐扩展。
  • 重申推荐:多数住院癌症伴急性内科疾病患者需全程住院期间血栓预防;不常规推荐所有门诊癌症患者预防;大手术癌症患者应术前开始预防并持续至少7-10天。

主要发现

  • 两项DOAC治疗癌症VTE的RCT报告,艾多沙班和利伐沙班有效,但与LMWH相比,在胃肠道和潜在泌尿生殖道癌症患者中出血风险更高。
  • 另两项RCT报告了DOAC用于VTE风险增加的门诊癌症患者血栓预防。

关键数值与推荐

  • 临床医生可向选定的高危门诊癌症患者提供阿哌沙班、利伐沙班或LMWH血栓预防。
  • 利伐沙班和艾多沙班已新增为VTE治疗选项。
  • 脑转移患者现已在VTE治疗章节中予以讨论。
  • 关于术后长期LMWH的推荐已扩展。
  • 多数住院癌症伴急性内科疾病患者需在整个住院期间进行血栓预防。

临床怎么用

  • 对高危门诊癌症患者可选择阿哌沙班、利伐沙班或LMWH进行血栓预防。
  • 癌症相关VTE治疗可考虑利伐沙班或艾多沙班作为选项。
  • 大手术癌症患者预防应从术前开始并持续至少7-10天。
  • 多数住院癌症伴急性内科疾病患者需全程住院期间血栓预防。
  • 应定期评估VTE风险并向患者教育VTE体征和症状。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To provide updated recommendations about prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer. METHODS: PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs published from August 1, 2014, through December 4, 2018. ASCO convened an Expert Panel to review the evidence and revise previous recommendations as needed. RESULTS: The systematic review included 35 publications on VTE prophylaxis and treatment and 18 publications on VTE risk assessment. Two RCTs of direct oral anticoagulants (DOACs) for the treatment of VTE in patients with cancer reported that edoxaban and rivaroxaban are effective but are linked with a higher risk of bleeding compared with low-molecular-weight heparin (LMWH) in patients with GI and potentially genitourinary cancers. Two additional RCTs reported on DOACs for thromboprophylaxis in ambulatory patients with cancer at increased risk of VTE. RECOMMENDATIONS: Changes to previous recommendations: Clinicians may offer thromboprophylaxis with apixaban, rivaroxaban, or LMWH to selected high-risk outpatients with cancer; rivaroxaban and edoxaban have been added as options for VTE treatment; patients with brain metastases are now addressed in the VTE treatment section; and the recommendation regarding long-term postoperative LMWH has been expanded. Re-affirmed recommendations: Most hospitalized patients with cancer and an acute medical condition require thromboprophylaxis throughout hospitalization. Thromboprophylaxis is not routinely recommended for all outpatients with cancer. Patients undergoing major cancer surgery should receive prophylaxis starting before surgery and continuing for at least 7 to 10 days. Patients with cancer should be periodically assessed for VTE risk, and oncology professionals should provide patient education about the signs and symptoms of VTE.Additional information is available at www.asco.org/supportive-care-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2019. PMID: 31381464. doi:10.1200/JCO.19.01461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。